The absolute Cardiovascular Disease (CVD) risk is a leading cause of death. Guidelines recommend treatment with lipid-modifying drugs for patients with an elevated CVD risk, since cholesterol target attainment allows a reduction of events. Our aim was to analyze the economic impact (drugs and hospitalizations) of LDL target attainment. METHODS: A multicenter, retrospective observational study using administrative and laboratory databases (1.1 million health-assisted individuals) was conducted. The enrolment date for a given patient was the last date in year 2009 in which the patient reached its LDL therapeutic target, accordingly to its CVD profile. Patients without statins prescriptions within the 18 months preceding the enrolment date were excluded. RESULTS: A total of 17,243 patients were enrolled (54.6% males, age 69,3Ϯ10,0). The annual standard cost for statins and cardiovascular hospitalizations to achieve the therapeutic target, obtained from a multivariable regression model, was €698. The standard annual requirements for welfare benefits, calculated on the basis of this approach, had a value of 14% lower (€2,914,807) than the current value of expenditure. This resource saving was attributable to a reduced spending in hospital admissions, likely due to a correct prevention. The standard requirements, however, showed a different items composition of expenditure; particularly, we observed an increase of the pharmaceutical expenditure by 13% (€1,022,825) compared to the current value. 42% of patients did not reach target (13% adherents, 29% non-adherents), 33% reached target (although nonadherents), consuming 28% of the total expenditure, suggesting an over-consumption of resources (27% used high dosages statins); this expenditure could be reallocated within the non-target groups, increasing the adherence and switching to other statins and/or dosages. CONCLUSIONS: The applicability of this approach and the costsaving achievement, needs the adoption of a reimbursement system that rewards the care pathway not only in its individual parts (ie, drug treatments).
OBJECTIVES:
To calculate US-hospital specific DRGs payments for in-patient stays with a primary diagnosis of stroke and assess its variability according to Medicare inpatient prospective payment system (IPPS). METHODS: The ICD 9-CM diagnosis codes related to stroke were selected. The coding rules and algorithms of the Medicare severity DRG Grouper (version V29) were analyzed to identify the distinct stroke related Diagnosis Related Groups (DRG) depending on co-morbidities and concomitant diagnosis. According to IPPS rules, inpatient hospital services are paid at a predetermined rate. This latter is calculated by multiplying a DRG-relative weight with operating and capital base payments rates. These rates are adjusted on several hospital features such as geographical area, share of low-income patients served, and involvement in medical education. These hospital specific DRG base payments were implemented for each Medicare provider listed in the Federal register, based on their information found in the 2012 PPS Impact files. Weighted average tariffs across DRG, based on discharges rates reported in the Health care Cost and Utilization Project (HCUP) statistics were generated and the variability of DRG payments was also assessed through descriptive statistics. RESULTS: Distinct DRGs are assigned during inpatient stay for stroke and their average payments to Medicare providers ranging from $4,288 to $18,296. Overall weighted mean (median) payments for stroke were $7,193 ($6,728) across all DRGs and Medicare providers. DRG-tariffs distributions by region as well as other hospital characteristics (size, urban versus rural location, teaching status) highlighted the disparities related to each of these factors and their relative impact. These findings were compared with HCUP aggregated statistics related to costs and hospital charges. CONCLUSIONS: Calculating hospital specific DRGs according to the US-Medicare prospective payment system enable to get reliable cost inputs for health-economic models and relevant for adaptation to US-local settings (regional or even hospital based). 
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OBJECTIVES:
To study warfarin compliance by Australian patients with Atrial Fibrillation (AF). METHODS: Longitudinal assessment of Pharmaceutical Benefit Scheme (PBS) claim records provided by Medicare Australia. We analysed a 10% random sample of all Australian long-term health concession card holders who had taken an anti-arrhythmic medication for AF prior to a new initiation of warfarin (time window October 2006 to September 2007), and for whom warfarin had not been dispensed in the 12 months prior to the initiation. Regimen complexity was assessed using the number of strengths of warfarin taken in a 90-day period. Treatment compliance was assessed using: the proportion failing to fill a second prescription; median persistence time with medication: long term persistence at 30 months. Treatment cessation was defined as 6 months without a warfarin prescription. RESULTS: The PBS Claims database yielded information on 1,108 concessional AF patients newly initiated on warfarin. These AF patients were initiated on 2.4 different strengths of warfarin in the first 3 months and the regimen complexity was 2.0 strengths 12 months later. Australian PBS claims data showed that 13% stopped warfarin after the first script. Median persistence to warfarin was 22 months, while long term persistence (30 months) was around 42%. Decreasing the cessation criteria from 6 to 3 months revealed large treatment gaps in 16% of warfarin patients at 2 years. CONCLUSIONS: There is a significant problem with complex dosing regimens and poor persistence in AF patients taking warfarin. Warfarin regimens tend to be complex with AF patients averaging 2 or more strengths of warfarin. Not only do the majority of AF patients stop warfarin within 2 years, a further one in six had large treatment gaps. If AF patients fail to take their anticoagulation therapy regularly, then this will substantially increase the risk of adverse outcomes including stroke. OBJECTIVES: Antihypertensive single-pill combination (SPC) therapy is known to be associated with better compliance and persistence compared to free-drug combinations (FC). However, due to differences in blood pressure, occurrence of hypertension-related diseases, diet, and lifestyle, applying the existing results from a Western population to a Korean population may not be acceptable. In this study, we compared the compliance and persistence of SPC versus FC using the 2009 data of the Health Insurance Review Agency National Patient Sample. METHODS: Among a total of 65,477,122 prescription claims, patients who were prescribed at least one SPC or FC in 2009, were more than 40 years old and had no history of hospitalization, surgery, or cancer numbered 9,822 and 7,494, respectively. Compliance was measured using the proportion of days covered (PDC) and calculated as the proportion of days a patient took the index drug within the 12-month follow-up period in 2009. Persistence with therapy was measured as the number of days from the index date to the therapy discontinuation date, which was defined as a gap in therapy of 30 or more days. RESULTS: The overall average PDC was 0.58 for SPC and 0.59 for FC, which was not significantly different. However, compliance varied by comorbidity status: patients who prescribed SPC showed greater PDC than those who were prescribed FC. Notably, among patients with dyslipidemia, diabetes, and chronic heart disease, compliance was significantly higher for SPC than for FC: 0.64 vs. 0.61 for dyslipidemia (pϭ0.0159), 0.63 vs. 0.60 for diabetes (pϭ0.0062), and 0.69 vs. 0.66 for chronic heart disease (pϭ0.0441). However, persistence was not significantly different in either the overall cohort or the cohort stratified by comorbidity. CONCLUSIONS: Our study suggests that use of SPC in hypertensive patients with comorbidities may provide clinical benefits by improving better compliance compared with patients taking FC. OBJECTIVES: Premature discontinuation of antiplatelet therapy after percutaneous coronary intervention (PCI) is a main predictor of late stent thrombosis which can lead to serious consequences such as death and acute myocardial infarction. We aim to assess the impact of patients' awareness of consequences of non-compliance on self-reported adherence with antiplatelet therapy after PCI. METHODS: We retrospectively analyzed 393 patients who underwent PCI with stent implantation from the Care For Your Heart database in Hong Kong. Patients were asked about their awareness of the risk of adverse cardiac events or death from noncompliance with anti-platelet therapy after PCI. Patients who were non-compliant (defined as self-reported missing more than 1 tablet per month) were compared to those who were compliant. RESULTS: Of the 393 patients, 35.6% (nϭ140) were unaware that non-compliance with anti-platelet therapy was associated with any risk, 50.9% (nϭ235) was aware of risk of adverse cardiac events or death, and 5.9% (nϭ23) were considered non-compliant with prescribed antiplatelet therapy after PCI. Non-compliant patients were predominantly male (91.3%) with an average age of 67.0Ϯ0.9 years, of whom 43.5% were not aware that non-compliance was associated with any risk compared to 35.9% (pϭ0.03) of compliant patients. Patients who were aware of the cardiac risks of non-compliance were more likely to adhere to their anti-platelet regimen (48.2% vs. 28.1%; pϭ0.03). More patients received their information on cardiovascular health from health talks (60.3%) and printed media (51.1%) than from their cardiologists (33.0%). CONCLUSIONS: Increased awareness of the dire consequences of non-compliance with anti-platelet therapy is needed among patients undergoing PCI. Health care providers are encouraged to better educate patients to optimize adherence to medication. 
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PCV81 AWARENESS OF SERIOUS CONSEQUENCES OF NON-COMPLIANCE AND SELF-REPORTED ADHERENCE TO ANTIPALTELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
PCV82 OBSERVATIONAL STUDY EVALUATING THE LEVEL OF COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS IN THE GREEK POPULATION
OBJECTIVES:
To evaluate the level of compliance with antihypertensive medication among Greek hypertensive patients. Furthermore, to investigate the possible association between non-compliance and patient profile as well as specific drug categories. METHODS: A total of 2700 hypertensive patients participated and 2662 were analyzed in the study. The duration of the study was 9 months. Information was collected on different antihypertensive drug categories along with epidemiological data. Morisky scale was used in order to measure compliance. RESULTS: A total of 57.5% of the responders were male (1530 patients) and 1130 were female. Average age of responders was 63 years and average duration of hypertension was 8.6 years. 63.1% of the study population was found to be compliant with their antihypertensive treatment (regardless of the type of antihypertensive treatment the patient was receiving). From the Morisky scale, 36.2% of patients answered that they sometimes forget to take their medication, 44.9% said that they were sometimes careless when it comes to taking their medicine, 26.9% that when they feel better they forget to take their medicine and 18.4% of the study population answered that when they feel worse, they relate this to their medication and discontinue taking it. The factors found to influence compliance were the level of education, the occupational status and the financial status of the patient as well as the existence of conforming diseases such as duslipidemia and diabetes. CONCLUSIONS: About four out of ten hypertensive patients fail to comply with their prescribed treatment, increasing the possibility of poor control of their condition. This may be an important obstacle in the assessment of the efficacy of any pharmaceutical therapy and may influence the overall health levels of the patients, since poorly controlled blood pressure may lead to the development of more serious conditions as Congestive Heart Failure and Coronary Heart Disease. 
PCV83 ADHERENCE TO ANTIHYPERTENSIVE AGENTS AFTER A RECENT ISCHEMIC STROKE AND RISK OF CARDIOVASCULAR OUTCOMES : A POPULATION BASED STUDY
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Antihypertensive agents have been shown to reduce the risk of major cardiovascular events. However, there are no large effectiveness studies which have assessed adherence to antihypertensive medications and major cardiovascular outcomes in high risk individuals who have recently suffered an ischemic stroke. To evaluate the relationship between antihypertensive (AH) drug adherence and cardiovascular (CV) outcomes among patients with a recent ischemic stroke and to assess the validity of our approach. METHODS: A cohort of 14,227 patients with an ischemic stroke was assembled from individuals 65 years and older who were treated with AH agents from 1999-2007 in the province of Quebec, Canada. A nested case-control design was used to evaluate the occurrence of nonfatal major CV outcomes, and mortality. Each case was matched to 15 controls by age and cohort entry time. Medication possession ratio was used for AH agents adherence level. Adjusted conditional logistic regression models were used to estimate the rate ratio of CV events. The validity of the approach was assessed by evaluating the impact of adherence to CV protective and non-CV protective drugs. RESULTS: Mean age was 75 years, 54% were male, 38% had coronary artery disease, 23% had diabetes, 47% dyslipidemia, and 14% atrial fibrillation or flutter. High adherence to AH therapy decreased the risk of non-fatal vascular events compared to lower level . Male gender and CV disease were risk factors for non-fatal vascular events. We observed a paradoxical relation between adherence to several drugs and mortality risk. CONCLUSIONS: Adherence to AH agents is associated with a risk reduction of non-fatal vascular events after a recent ischemic stroke. Overestimation of an all-cause mortality reduction may be related to frailty and comorbidity which may confound the apparent benefits of different drugs.
PCV84 MISDIAGNOSIS AND MISTREATMENT OF ACE-INHIBITOR INDUCED COUGH DECREASES THERAPY COMPLIANCE
Vegter S, de Boer P, van Dijk KW, Visser ST, de Jong-van den Berg LT University of Groningen, Groningen, The Netherlands OBJECTIVES: A common adverse effect of angiotensin-converting enzyme inhibitors (ACEi) is a persistent dry cough. Physicians and pharmacists who fail to recognise dry cough to be ACEi related may prescribe cough suppressants (antitussives), instead of recommended ACEi substitution. The aim of this study was to determine the amount of antitussive treatment of ACEi-induced cough and the influence of this on therapy compliance. METHODS: Prescription data from community pharmacies between 2000 and 2012 were retrieved from the IADB.nl database in The Netherlands. A prescription sequence symmetry analysis was used to determine whether antitussive agents were prescribed more often following ACEi initiation than the other way around. Therapy compliance was assessed using the proportion of days covered (PDC) method; patients with a PDC Ն80% were considered compliant. RESULTS: A total of 1898 starters of ACEi and antitussives within a half-year time span were included. A significant excess of patients received antitussives after ACEi initiation (1,269 versus 629), yielding a sequence ratio of 2.0 (CI: 1.8 -2.2). The estimated proportion of patients with ACEi induced cough receiving antitussives decreased over time: from 20.4% in 2000-2004 to 8.0% in 2008-2012 . Therapy compliance in patients receiving antitussives due to ACEi initiation was 52.4%, significantly lower than compliance in control patients, which was 75.2% (PϽ0.001). CONCLUSIONS: Many patients receive cough suppressants after ACEi initiation. This suggests that ACEi induced cough is often either not recognized as being ACEi related or is symptomatically treated. Such prescription behaviour is ineffective and potentially harmful; it also decreases therapy compliance with ACE inhibitors. The correct identification and management of this adverse drug effect is an important aspect of pharmaceutical care. We identified patients from 3 health care providers with different percentages of subsidy to buy a medication using the same service in PBM the first provider subsidizes 100%, the second subsidizes 90% (generic) and 70% (brand) and third subsidizes 40%. We selected patients with age Ն 40 years male and female. The persistence analysis was made in the 12 months that followed from the first acquisition within the using method MPR (Medication Possession Ratio). 
PCV85 PERSISTENCE OF PATIENTS TREATED HYPERTENSIVE MEDICATION IN PBM WITH DIFFERENT PERCENTAGES OF FINANCIAL SUBSIDY
OBJECTIVES:
To determine loss of health status, work productivity impairment, and activity impairment associated with non-adherent cost-cutting in Russian hypertension patients. METHODS: The study employed data from the 2011 Russia National Health and Wellness Survey (NHWS; nϭ10,039), a survey of demographics, health-related attitudes and behaviors, and health outcomes. Non-adherent cost-cutting behaviors included taking less medication than prescribed, cutting tablets in half, buying fewer tablets, not buying prescriptions recommended by the physician, buying a less expensive alternative instead, or buying prescriptions less often. Adherent behaviors included asking physician/ pharmacist for cheaper alternatives, or using a discount card. Health status was assessed using the SF-12v2, and work and activity impairment using the Work and Activity Impairment questionnaire (WPAI). Regression models quantified the burden associated with nonadherent cost-cutting on health status and WPAI metrics, controlling for demographics, health history, insurance status, and comorbidities. RESULTS: Out of 1,712 diagnosed hypertension patients taking prescription medication for hypertension, 37.5% reported using non-adherent cost-cutting behaviors, 28.2% reported using adherent cost-cutting behaviors only, and 34.3% reported no cost-cutting behaviors. After controlling for covariates, employed patients using non-adherent strategies reported greater absenteeism (9.3% vs. 3.7%, pϭ0.002), presenteeism (29.2% vs. 21.8%, pϽ0.001) and overall work productivity loss (33.8% vs. 24.3%, pϽ0.001) compared with employed patients who do not use those strategies. Among all respondents, non-adherent cost-cutting was associated with lower adjusted health status (MCS: 42.0 vs. 44.4, pϽ0.001, PCS: 40.3 vs. 41.3, pϭ0 .014) and greater adjusted activity impairment (38.5% vs. 31.2%, pϽ0.001). CONCLUSIONS: Over a third of hypertension patients cut costs using strategies that interfere with medication adherence. These patients suffer greater health-related impairments in work and non-work activities and have lower health status. These patients should be identified and guided to improve adherence to their prescription medications to facilitate better health outcomes. OBJECTIVES: Medication non-adherence and treatment satisfaction are significant barriers to achieving treatment outcomes and associated with increased health care costs among patients with hypertension. Using a novel patient registry, we assessed factors associated with satisfaction and non-adherence to hypertension medications. METHODS: We analyzed data from MediGuard.org, a free medication monitoring service covering over 2.6 million members in the US, UK, France, Germany, Spain, and Australia. As part of site operations, the service sends a quarterly member survey to solicit feedback on their medications using the Treatment Satisfaction Questionnaire for Medication (TSQM) and Medication Adherence Report A377 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
PCV87 FACTORS RELATED TO NON-ADHERENCE AND SATISFACTION FOR HYPERTENSION MEDICATIONS: RESULTS FROM A NOVEL PATIENT REGISTRY
